Moreover, by examining cohorts of cancer patients undergoing ICI therapy, particularly those receiving anti-PD-1 and anti-PD-L1 treatments, it was observed that patients with high SUSD3 expression had significantly better survival rates and longer response durations compared to those with low SUSD3 expression. The gene discussed is SUSD3; the disease is cancer.